Shorter but not more catalytic: an active-site-resolved model of how tau reshapes amyloid-$β$ secondary nucleation

Abstract

Tau cross-seeding creates a mechanistic puzzle. Tau fibrils accelerate amyloid-$β$42 (A$β$42) nucleation and produce a larger population of shorter A$β$ fibrils, yet homotypic secondary nucleation occurs at rare catalytic sites rather than uniformly over fibril mass. Does making more, shorter fibrils make the A$β$ population more catalytic? A coupled tau-A$β$ model is extended to track fibril number, fibril mass, total active secondary-nucleation sites, and the fraction of sites exposed after plaque consolidation. The model recovers the preceding plaque-surface-limited formulation when active sites form in direct proportion to fibril mass. At matched fibril mass, shortening alone has little effect: the departure of active-site density from mass proportionality scales inversely with mean fibril size, so the extra fibrils matter only if each birth event introduces about as many sites as elongation adds over a mean-length fibril. At equal time, the sign of the homotypic response is controlled mainly by a Damkohler number comparing monomer consumption by elongation with monomer clearance. Tau coupling increases homotypic secondary nucleation while clearance controls free monomer, but suppresses it once elongation becomes the dominant monomer sink. In a composite scenario, these regimes occur in sequence. Across all cases examined, including 800 Latin-hypercube samples and simulations with mean fibril lengths of 0.3-30 $μm$, direct tau catalysis increases accumulated oligomer-equivalent exposure. The model predicts that shorter tau-seeded fibrils are not intrinsically more catalytic unless their sites are more numerous per unit mass, more active, or more exposed; matched-mass site counting and secondary-nucleation measurements can distinguish these alternatives.